New webinar with Kirsten Müller-Vahl

On Thursday, 28 April, Prof. Dr. Kirsten Müller-Vahl will be a guest in the webinar of the Bedrocan Series. Müller-Vahl is a Professor of Psychiatry in the Department of Psychiatry, Social Psychiatry and Psychotherapy at the Hanover Medical School in Germany. Müller-Vahl has been researching the effect of medicinal cannabis in the treatment of tics and other psychiatric disorders for more than twenty years. In this webinar, Müller-Vahl shares the the most recent CANNA-TICS study results in which the effect of nabiximol was investigated in Gilles de la Tourette patients. She will also speak first-hand about an unpublished study on the use of cannabis among German patients.

As the webinar is a live event, there will be the opportunity to ask questions.

webinar with Kirsten Müller-Vahl

Bio dr. Kirsten Müller-Vahl

Dr. Kirsten R. Müller-Vahl is a Professor of Psychiatry at the Department of Psychiatry, Socialpsychiatry and Psychotherapy at the Hannover Medical School (MHH), Germany. She is a specialist in both neurology and adult psychiatry. In the last 20 years she has investigated more than 1500 patients with Tourette syndrome (TS) (children and adults).

Since 1994 Müller-Vahl has been studying the clinical effects of cannabinoids in the treatment of movement disorders. Subsequently, she performed several studies investigating the effect of delta-9-tetrahydrocannabinol in the treatment of tics and other psychiatric disorders.

Müller-Vahl is a member of the scientific advisory board of the Tourette Society Germany and a board member of the International Working Group for Cannabinoid Medicines (IACM).

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text.

Start typing and press Enter to search